Undisclosed FAN1 nuclease modulator / Harness Therap - LARVOL DELTA

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases (BioSpace) - "Harness Therapeutics...announces that it has successfully raised an additional £4 million in funding from its existing investors, bringing the total invested to £17.6 million. Proceeds will be used to advance Harness’ lead Huntington’s Disease (HD) programme targeting FAN1 nuclease and pursue target discovery and validation activities in other neurodegenerative disease pathways."

Financing • CNS Disorders • Huntington's Disease